A premium was paid on the Class A common stock by G42 Investments of $ 18.7 million, net of a note receivable discount of $ 0.6 million, which was deferred and recorded as a contract liability.
The Company will receive royalties in the single digits from G42 Healthcare on the net sales of cadisegliatin for a period of at least ten years after the first commercial sale of cadisegliatin in th…
vTv Therapeutics Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
VTVT-DEBT-13465
Warrants outstanding: 167000
90%
xbrl warrant detail from xbrl 2023-12-31.
VTVT-DEBT-13466
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2018-12-31.
vTv Therapeutics Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for vTv Therapeutics Inc..
vTv Therapeutics Inc. Ownership
Holder
Name
Confidence
Evidence
VTVT-OWNER-SAMSARA-BIOCAPITAL-LLC
SAMSARA BIOCAPITAL, LLC
90%
13F overlay lists SAMSARA BIOCAPITAL, LLC as top holder; 35 tracked holders.
vTv Therapeutics Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
